RI-001 in Immunosuppressed Respiratory Syncytial Virus (RSV) Infected Patients at Risk of Lower Tract RSV Illness

PHASE2CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

February 29, 2008

Primary Completion Date

May 31, 2010

Study Completion Date

May 31, 2010

Conditions
Upper Respiratory Tract InfectionLower Respiratory Tract Infection
Interventions
BIOLOGICAL

RI-001

Dose 1

BIOLOGICAL

RI-001

Dose 2

BIOLOGICAL

RI-001

Placebo

Trial Locations (19)

11040

Schneider Children's Hospital, New Hyde Park

14642

University of Rochester Medical Center, Rochester

20010

Children's National Medical Center, Washington D.C.

21205

Johns Hopkins Medical Center, Baltimore

33701

All Children's Hospital, St. Petersburg

60612

Rush University Medical Center, Chicago

75235

Children's Medical Center of Dallas, Dallas

76104

Cook Children's Medical Center, Fort Worth

80045

University of Colorado Health Sciences Center, Aurora

94143

University of California San Francisco, San Francisco

97239

Oregon Health and Science University, Portland

98105

Seattle Children's Hospital and Regional Medical Center, Seattle

98109

Fred Hutchinson Cancer Research Center, Seattle

02111

New England Medical Center, Boston

07601

Hackensack University Medical Center, Hackensack

T3B6A8

Alberta Children's Hospital, Calgary

M5G1X8

Hospital for Sick Children, Toronto

H1T2M4

Hopital Maisonneuve Rosemont, Montreal

H3T1C5

Hopital Sainte Justine, Montreal

Sponsors
All Listed Sponsors
lead

ADMA Biologics, Inc.

INDUSTRY